Last reviewed · How we verify
CN128 Tablets
CN128 Tablets' mechanism is currently unknown.
At a glance
| Generic name | CN128 Tablets |
|---|---|
| Also known as | CN128 |
| Sponsor | Hangzhou Zede Pharma-Tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
No information is available on the exact mechanism of action of CN128 Tablets.
Approved indications
Common side effects
Key clinical trials
- Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients (PHASE2)
- Long-term Clinical Study of CN128 in Thalassemia Patients (PHASE2)
- Short-term Clinical Study of CN128 in Thalassemia Patients (PHASE1)
- Clinical Study of CN128 in Thalassemia Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CN128 Tablets CI brief — competitive landscape report
- CN128 Tablets updates RSS · CI watch RSS
- Hangzhou Zede Pharma-Tech Co., Ltd. portfolio CI